Page last updated: 2024-11-05

trimetrexate and Leukemia, Myeloid, Acute

trimetrexate has been researched along with Leukemia, Myeloid, Acute in 1 studies

Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kheradpour, A1
Berman, E1
Göker, E1
Lin, JT1
Tong, WP1
Bertino, JR1

Trials

1 trial available for trimetrexate and Leukemia, Myeloid, Acute

ArticleYear
A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia.
    Cancer investigation, 1995, Volume: 13, Issue:1

    Topics: Adult; Aged; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Precursor Cell

1995